Clinical Trials Logo

Filter by:
NCT ID: NCT02136511 Approved for marketing - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Start date: n/a
Phase: N/A
Study type: Expanded Access

This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.

NCT ID: NCT02136459 Completed - Thyroidectomy Clinical Trials

Non-neural Vocal Changes After Thyroidectomy

Start date: October 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to test the investigators hypothesis that intubation with a smaller ETT would lead to reduced postoperative vocal impairment and laryngoscopic evidence of laryngeal trauma than intubation with a standard size ETT.

NCT ID: NCT02130362 Active, not recruiting - Crohn's Disease Clinical Trials

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

CAPE
Start date: August 28, 2014
Phase:
Study type: Observational

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.

NCT ID: NCT02129699 Terminated - Clinical trials for Lung Cancer Non-small Cell Stage IV

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy

SPLENDOUR
Start date: January 6, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate how well the standard treatment (platinum-based doublet chemotherapy) in combination with denosumab works compared with the standard treatment alone in patients with a type of lung cancer called "non small cell lung cancer" (NSCLC) that has spread to other parts of the body.

NCT ID: NCT02123823 Completed - Neoplasms Clinical Trials

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Start date: May 15, 2014
Phase: Phase 1
Study type: Interventional

Phase Ib / II study to determine the Maximum Tolerated Dose and Recommended Phase II Dose, and to evaluate the safety and antitumour activity, of BI 836845 and everolimus in combination with exemestane in women with HR+/HER2- advanced breast cancer

NCT ID: NCT02122978 Active, not recruiting - Psoriasis Clinical Trials

Comparing Mindfulness Based Cognitive Therapy and Mindfulness Based Self-compassion Therapy in a Psoriasis Sample

Start date: November 2013
Phase: N/A
Study type: Interventional

Increasing research evidence supports the effectiveness of mindfulness based interventions; however, the exact mechanisms of change are poorly understood. Some evidence proposes that self-compassion is an important mechanism of change in the effectiveness of mindfulness based interventions. The current research will evaluate and compare the effectiveness of two mindfulness meditation approaches; Mindfulness Based Cognitive Therapy (MBCT) and Mindfulness based Self-compassion Therapy (MBSCT), for individuals with psoriasis, a skin condition commonly associated with stress. Blood analyses will be conducted to assess and compare the impact of the interventions on the immune system. Self-report questionnaires will explore participants' psychological functioning (e.g. self-compassion, depression, anxiety, worry). This study will also examine whether a relationship exists between immune functioning and psychological factors. An audio-guided MBSCT programme will be piloted, with a view to trialling as a more cost-effective alternative to traditional mindfulness interventions. Findings will enable us to design more effective interventions in the future, and yield clear results regarding the existence of a definite link between immunological functioning and psychological functioning. The main research hypothesis is that participants who complete a mindfulness based intervention will experience significantly greater psychological well-being, symptom reduction, and greater changes in telomerase and cytokine activity than individuals who only receive treatment as usual for their psoriasis.

NCT ID: NCT02119663 Terminated - Pancreatic Cancer Clinical Trials

A Study of Ruxolitinib in Pancreatic Cancer Patients

Start date: June 2014
Phase: Phase 3
Study type: Interventional

This was to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer.

NCT ID: NCT02118896 Completed - Clinical trials for Kidney Transplantation

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

Start date: February 24, 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study was to offer patients who had participated in one of the phase II PK or phase III studies on FK506E (MR4) the possibility to continue FK506E (MR4) until commercial availability of the drug and to record long term efficacy and safety data.

NCT ID: NCT02112877 Completed - Clinical trials for Chronic Venous Disorder

VIRTUS: An Evaluation of the Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow Obstruction

VIRTUS
Start date: June 26, 2014
Phase: N/A
Study type: Interventional

This is a prospective, multi-center, single arm, non-randomized study to define safety and efficacy of the Veniti Vici™ Venous Stent System in relation to pre-defined Objective Performance goals. A maximum of 200 patients at up to 45 centers worldwide will be enrolled. Thirty (30) feasibility patients will be enrolled at approximately 7-10 centers and 170 pivotal patients will be enrolled at approximately 45 centers worldwide. The follow-up period is 36 months.

NCT ID: NCT02109666 Completed - Clinical trials for Rheumatoid Arthritis

Long Term Experience With Abatacept in Routine Clinical Practice

ACTION
Start date: March 2008
Phase: N/A
Study type: Observational

The purpose of this study is to estimate the retention rate of Abatacept over 24 months in routine clinical practice in every participating country depending on the treatment line.